Transdermal drug pharmacokinetics in man: Interindividual variability and partial prediction

International Journal of Pharmaceutics

Volumn 367, Issue 1-2, 2009, Pages 1-15

  Farahmand, Sara ^a   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Interindividual variation; Pharmacokinetics; QSPR; Skin absorption; Transdermal drug delivery; Transdermal patch

Indexed keywords

CLONIDINE; ESTRADIOL; ESTRADIOL PLUS LEVONORGESTREL; ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRADOT; ESTRONE; ETHINYLESTRADIOL PLUS NORELGESTROMIN; FENTANYL; GLYCERYL TRINITRATE; METHYLPHENIDATE; N DESETHYL OXYBUTYNIN; NAP 226090; NEURPO; NICOTINE; NICOTINE GUM; NOOTROPIC AGENT; OXYBUTYNIN; RIVASTIGMINE; SCOPOLAMINE; SELEGILINE; TESTOSTERONE; TRADELIA; UNCLASSIFIED DRUG; URINARY TRACT SPASMOLYTIC AGENT;

DRUG ABSORPTION; DRUG ELIMINATION; DRUG METABOLISM; HYDROGEN BOND; KINETICS; LIPOPHILICITY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SKIN PERMEABILITY; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; BIOLOGICAL AVAILABILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SKIN ABSORPTION; THERAPEUTIC EQUIVALENCY;

EID: 58249116904     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.11.020     Document Type: Review

References (82)

1. Abraham M.H., and Martins F. Human skin permeation and partition: general linear free-energy relationship analyses. J. Pharm. Sci. 93 (2004) 1508-1523
2. Abraham M.H., Chadha H.S., and Mitchell R.C. The factors that influence skin penetration of solutes. J. Pharm. Pharmacol. 47 (1995) 8-16
3. Abrams L.S., Skee D.M., Natarajan J., Wong F.A., and Anderson G.D. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. Br. J. Clin. Pharmacol. 53 (2002) 141-146
4. Abrams L.S., Skee D.M., Natarajan J., Wong F.A., Leese P.T., Creasy G.W., and Shangold M.M. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. J. Clin. Pharmacol. 41 (2001) 1301-1309
5. Amory J.K., Kalhorn T.F., and Page S.T. Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception. J. Androl. 29 (2008) 260-271
6. Anderson V.R., and Scott L.J. Methylphenidate transdermal system in attention-deficit hyperactivity disorder in children. Drugs 66 (2006) 1117-1126
7. Appell R.A., Chancellor M.B., Zobrist R.H., Thomas H., and Sanders S.W. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin. Proc. 78 (2003) 696-702
8. Auclair B., Sirois G., Ngoc A.H., and Ducharme M.P. Novel pharmacokinetic modelling of transdermal nitroglycerin. Pharm. Res. 15 (1998) 614-619
9. Auclair B., Sirois G., Ngoc A.H., and Ducharme M.P. Population pharmacokinetics of nitroglycerin and of its two metabolites after a single 24-hour application of a nitroglycerin transdermal matrix delivery system. Ther. Drug Monit. 20 (1998) 607-611
10. Azzaro A.J., Ziemniak J., Kemper E., Campbell B.J., and VanDenBerg C. Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J. Clin. Pharmacol. 47 (2007) 1256-1267
11. Baracat E., Haidar M., Castelo A., Tufik S., de Lima G.R., Vieira J.G., Peloso U., and Casoy J. Comparative bioavailability study of a once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women. Maturitas 23 (1996) 285-291
12. Bannon Y.B., Corish J., Corrigan O.I., Devane J.G., Kavanagh M., and Mulligan S. Transdermal delivery of nicotine in normal human volunteers: a single dose and multiple dose study. Eur. J. Clin. Pharmacol. 37 (1989) 285-290
13. Barratt M.D. Quantitative structure-activity relationships for skin permeability. Toxic. In Vitro 9 (1995) 27-37
14. Berner B. Pharmacokinetics of transdermal drug delivery. J. Pharm. Sci. 74 (1985) 718-721
15. Berner B., and John V.A. Pharmacokinetic characterization of transdermal delivery systems. Clin. Pharmacokinet. 26 (1994) 121-134
16. Boyd R.A., Zegarac E.A., Eldon M.A., Sedman A.J., and Forgue S.T. Characterization of a 7 day 17 beta-estradiol transdermal delivery system: pharmacokinetics in healthy postmenopausal women. Biopharm. Drug Dispos. 17 (1996) 459-470
17. Brocks D.R., Meikle A.W., Boike S.C., Mazer N.A., Zariffa N., Audet P.R., and Jorkasky D.K. Pharmacokinetics of testosterone in hypogonadal men after transdermal delivery: influence of dose. J. Clin. Pharmacol. 36 (1996) 732-739
18. Buch A.B., Shen L.Z., Kelly S.C., Russell D.A., Sahota R.S., Bixler C.A., Moehrke W., and Powell J.H. Significant differences in estradiol bioavailability from two similarly labelled estradiol matrix transdermal systems. Climacteric 2 (1999) 248-253
19. Bur A., Joukhadar C., Klein N., Herkner G., Mitulovic R., Schmid E., Agneter M., Müller M., and Brunner. Effect of exercise on transdermal nicotine release in healthy habitual smokers. Int. J. Clin. Pharmacol. Ther. 43 (2005) 239-243
20. Burlacu C.L., Frizelle H.P., Moriarty D.C., and Buggy D.J. Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. Regional Anesth. Pain Med. 32 (2007) 136-145
21. Cronin M.T.D., Dearden J.C., Moss G.P., and Murray-Dickson G. Investigation of the mechanism of flux across human skin in vitro by quantitative structure-permeability relationships. Eur. J. Pharm. Sci. 7 (1999) 325-330
22. Cummings J., Lefevre G., Small G., and Appeldingemanse S. Pharmacokinetic rationale for rivastigmine patch. Neurology 69 (2007) S10-S13
23. Devineni D., Skee D., Vaccaro N., Massarella J., Janssens L., LaGuardia K.D., and Leung A.T. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J. Clin. Pharmacol. 47 (2007) 497-509
24. Fant R.V., Henningfield J.E., Shiffman S., Strahs K.R., and Reitberg D.P. A pharmacokinetic crossover study to compare the absorption characteristics of three transdermal nicotine patches. Pharmacol. Biochem. Behav. 67 (2000) 479-482
25. Feldmann R.J., and Maibach H.I. Absorption of some organic compounds through the skin in man. J. Invest. Dermatol. 54 (1970) 399-404
26. Fujimura A., Ebihara A., Ohashi K., Shiga T., Kumagai Y., Nakashima H., and Kotegawa T. Comparison of the pharmacokinetics, pharmacodynamics, and safety of oral (Catapres) and transdermal (M-5041T) clonidine in healthy subjects. J. Clin. Pharmacol. 34 (1994) 260-265
27. Gorsline J., Okerholm R.A., and Rolf C.N. Comparison of plasma nicotine concentrations after application of Nicoderm (nicotine transdermal system) to different skin sites. J. Clin. Pharmacol. 32 (1992) 576-581
28. Grond S., Radbruch L., and Lehmann K.A. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin. Pharmacokinet. 38 (2000) 59-89
29. Guichard J.P., Sauron R., and Jones A.B. Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems. J. Clin. Pharmacol. 39 (1999) 811-816
30. Gupta S.K., Okerholm R.A., Coen P., Prather R.D., and Grosline J. Single- and multiple-dose pharmacokinetics of Nicoderm (Nicotine Transdermal System). J. Clin. Pharmacol. 33 (1993) 169-174
31. Gupta S.K., Okerholm R.A., Eller M., Wei G., Rolf C.N., and Gorsline J. Comparison of the pharmacokinetics of two nicotine transdermal systems: nicoderm and habitrol. J. Clin. Pharmacol. 35 (1995) 493-498
32. Gupta S.K., Southam M., Gale R., and Huang S.S. System functionality and physicochemical model of fentanyl transdermal system. J. Pain Symptom Manage. 7 (1992) S17-26
33. Guy R.H., and Hadgraft J. Pharmacokinetic interpretation of the plasma levels of clonidine following transdermal delivery. J. Pharm. Sci. 74 (1985) 1016-1018
34. Hansch C., Leo A., and Hoekman D. Exploring QSAR (1995), ACS, Washington D.C. PP. 54, 158, 164, 178, 169, 124, 127, 113, 150, 6, 76 and 173
35. Harrison L.L., and Harari D. An evaluation of bioequivalence of two 7-day 17beta-estradiol transdermal delivery systems by anatomical site. J. Clin. Pharmacol. 42 (2002) 1134-1141
36. Harrison L.I., Zurth C., Gunther C., Karara A.H., Melikian A., and Lipp R. Simultaneous estradiol and levonorgestrel transdermal delivery from a 7-day patch: in vitro and in vivo drug deliveries of three formulations. Drug Dev. Ind. Pharm. 33 (2007) 373-380
37. Hossain M., Quebe-Fehling E., Sergejew T., Schmidt G., Skerjanec A., Ibarra de Palacios P., and Krinsky L. Dose proportionality study of four doses of an estradiol transdermal system. Estradot. Maturitas 46 (2003) 173-185
38. Hossain M., Quebe-Fehling E., Sergejew T., Schmidt G., Skerjanec A., Cohen A., Krinsky L., and Ibarra de Palacios P. Comparative bioequivalence studies with Estradot and Menorest transdermal systems. Maturitas 46 (2003) 187-198
39. Ito M.K., and O'Connor D.T. Skin pretreatment and the use of transdermal clonidine. Am. J. Med. 91 (1991) S42-49
40. Lefèvre G., Sedek G., Huang H.L., Saltzman M., Rosenberg M., Kiese B., and Fordham P. Pharmacokinetics of a rivastigmine transdermal patch formulation in healthy volunteers: relative effects of body site application. J. Clin. Pharmacol. 47 (2007) 471-478
41. Lefèvre G., Sedek G., Jhee S.S., Leibowitz M.T., Huang H.L., Enz A., Maton S., Ereshefsky L., Pommier F., Schmidli H., and Appel-Dingemanse S. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin. Pharmacol. Ther. 83 (2008) 106-114
42. Lipinski C.A., Lombardo F., Dominy B.W., and Feeny P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46 (2001) 3-26
43. MacGregor T.R., Matzek K.M., Keirns J.J., van Wayjen R.G., van den Ende A., and van Tol R.G. Pharmacokinetics of transdermally delivered clonidine. Clin. Pharmacol. Ther. 38 (1985) 278-284
44. McClellan K.J., and Goa K.L. Transdermal testosterone. Drugs 55 (1998) 253-2578 discussion 259
45. Meikle A.W., Arver S., Dobs A.S., Sanders S.W., Rajaram L., and Mazer N.A. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site-a clinical research center study. J. Clin. Endocrinol. Metab. 81 (1996) 1832-1840
46. Mercier F., Lefèvre G., Huang H.L., Schmidli H., Amzal B., and Appel-Dingemanse S. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr. Med. Res. Opin. 23 (2007) 3199-3204
47. Müller P., Botta L., and Ezzet F. Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system. Eur. J. Clin. Pharmacol. 51 (1996) 327-330
48. Noonan P.K., Gonzalez M.A., Ruggirello D., Tomlinson J., Babcock-Atkinson E., Ray M., Golub A., and Cohen A. Relative bioavailability of a new transdermal nitroglycerin delivery system. J. Pharm. Sci. 75 (1986) 688-691
49. Physician's Desk Reference, 2006, 60th ed., Thompson PDR, New Jersey.
50. Ponti F.D.E., Luca C., and Pamparana F. Bioavailability study of three transdermal nitroglycerin preparations in normal volunteers. Curr. Ther. Res. 46 (1989) 111-120
51. Potts R.O., and Guy R.H. Predicting skin permeability. Pharm. Res. 9 (1992) 663-669
52. Prather R.D., Tu T.G., Rolf C.N., and Grosline J. Nicotine pharmacokinetics of Nicoderm (nicotine transdermal system) in women and obese men compared with normal-sized men. J. Clin. Pharmacol. 33 (1993) 644-649
53. Reginster J.Y., Donazzolo Y., Brion N., and Lins R. Estradiol pharmacokinetics after transdermal application of patches to postmenopausal women: matrix versus reservoir patches. Climacteric 3 (2000) 168-175
54. Reginster J.Y., Albert A., Deroisy R., Colette J., Vrijens B., Blacker C., Brion N., Caulin F., Mayolle C., Regnard A., Scholler R., and Franchimont P. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50. Maturitas 27 (1997) 179-186
55. Renner U.D., Oertel R., and Kirch W. Pharmacokinetics and pharmacodynamics in clinical use of scopolamine. Ther. Drug Monit. 27 (2005) 655-665
56. Ridout G., Santus G.C., and Guy R.H. Pharmacokinetic considerations in the use of newer transdermal formulations. Clin. Pharmacokinet. 15 (1988) 114-131
57. Riedel D.J., Wick K.A., Hawkinson R.W., Kolars C.A., Crowley J.K., Armstrong K.E., Chang S.F., Harrison L.I., and de Dennis S.R. Performance of a new transdermal nitroglycerin adhesive patch formulation. Clin. Ther. 11 (1989) 225-231
58. Rohatagi S., Barrett J.S., DeWitt K.E., and Morales R.J. Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm. Drug Dispos. 18 (1997) 567-584
59. Rohatagi S., Barrett J.S., McDonald L.J., Morris E.M., Darnow J., and DiSanto A.R. Selegiline percutaneous absorption in various species and metabolism by human skin. Pharm. Res. 14 (1997) 50-55
60. Rohr U.D., Nauert C., and Stehle B. 17Beta-estradiol delivered by three different matrix patches 50 microg/day: a three way cross-over study in 21 postmenopausal women. Maturitas 33 (1999) 45-58
61. Roskos K.V., and Maibach H.I. Percutaneous absorption and age: implications for therapy. Drugs Aging 2 (1992) 432-449
62. Sambol N.C., Harper C.C., Kim L., Liu C.Y., Darney P., and Raine T.R. Pharmacokinetics of single-dose levonorgestrel in adolescents. Contraception 74 (2006) 104-109
63. Scheuplein R.J., and Blank I.H. Permeability of the skin. Physiol. Rev. 51 (1971) 707-747
64. Schiffer R., Neis M., Holler D., Rodriguez F., Geier A., Gartung C., Lammert F., Dreuw A., Zwadlo-Klarwasser G., Merk H., Jugert F., and Baron J.M. Active influx transport is mediated by members of the organic anion transporting polypeptide family in human epidermal keratinocytes. J. Invest. Dermatol. 120 (2003) 285-291
65. Schwartz J.B. The influence of sex on pharmacokinetics. Clin. Pharmacokinet. 42 (2003) 107-121
66. Sobue S., Sekiguchi K., Kikkawa H., Akasaki M., and Irie S. Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking. Biol. Pharm. Bull. 29 (2006) 1068-1073
67. Solassol I., Caumette L., Bressolle F., Garcia F., Thézenas S., Astre C., Culine S., Coulouma R., and Pinguet F. Inter- and intra-individual variability in transdermal fentanyl absorption in cancer pain patients. Oncol. Rep. 14 (2005) 1029-1036
68. Sun J.X., Piraino A.J., Morgan J.M., Joshi J.C., Cipriano A., Chan K., and Redalieu E. Comparative pharmacokinetics and bioavailability of nitroglycerin and its metabolites from Transderm-Nitro, Nitrodisc, and Nitro-Dur II systems using a stable-isotope technique. J. Clin. Pharmacol. 35 (1995) 390-397
69. Tanner T., and Marks R. Delivering drugs by transdermal route: review and comment. Skin Res. Technol. 14 (2008) 249-260
70. Thompson J.P., Bower S., Liddle A.M., and Rowbotham D.J. Perioperative pharmacokinetics of transdermal fentanyl in elderly and young adult patients. Br. J. Anaesth. 81 (1998) 152-154
71. Tse F.L., and Laplanche R. Absorption, metabolism and disposition of [14C]SDZ ENA.713 an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration. Pharm. Res. 15 (1998) 1614-1620
72. Tur E. Physiology of the skin-differences between women and men. Clin. Dermatol. 15 (1997) 5-16
73. Vasil'ev A.E., Krasnyuk I.I., Ravikumar, and Tokhmakhchi V.N. Drug synthesis methods and manufacturing technology transdermal therapeutic systems for controlled drug release. Pharm. Chem. J. 35 (2001) 613-626
74. Vecchia B.E., and Bunge A.L. Evaluating the transdermal permeability of chemicals. In: Guy R.H., and Hadgraft J. (Eds). Transdermal Drug Delivery (2003), Marcel Dekker, New York 25-57
75. Wester R.C., and Maibach H.I. Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. Drug Metab. Rev. 14 (1983) 169-205
76. Williams A.C. Transdermal and Topical Drug Delivery (2003), Pharmaceutical Press, London pp. 178-187
77. Wolff M., Cordes G., and Luckow V. In vitro and in vivo release of nitroglycerin from a new transdermal therapeutic system. Pharm. Res. 2 (1985) 23-29
78. Yalkowsky S.H. Solubility and partitioning V: dependence of solubility on melting point. J. Pharm. Sci. 70 (1981) 971-973
79. Yu D.K., Williams R.L., Benet L.Z., Lin E.T., and Giesing D.H. Pharmacokinetics of nitroglycerin and metabolites in humans following oral dosing. Biopharm. Drug Dispos. 9 (1988) 557-565
80. Zacur H.A., Hedon B., Mansour D., Shangold G.A., Fisher A.C., and Creasy G.W. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil. Steril. 77 (2002) S32-S35
81. Zobrist R.H., Quan D., Thomas H.M., Stanworth S., and Sanders S.W. Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system. Pharm. Res. 20 (2003) 103-109
82. Zobrist R.H., Schmid B., Feick A., Quan D., and Sanders S.W. Pharmacokinetics of the R- and S-enantiomers of oxybutynin and N-desethyloxybutynin following oral and transdermal administration of the racemate in healthy volunteers. Pharm. Res. 18 (2001) 1029-1034